Decibel Therapeutics, Inc. Common Stock

DBTX

Börsenwert 123 Mio. $

Profil: Decibel Therapeutics Inc is a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments for hearing and balance disorders. It aims to restore and improve hearing and balance through the restoration and regeneration of functional hair cells and non-sensory support cells within the inner ear. Its lead gene therapy product candidate is DB-OTO which provides hearing to individuals born with profound hearing loss due to an OTOF deficiency. The firm's pipeline products comprise DB-ATO, AAV.103, AAV.104, AAV.201, DB-020, and Cochlear Hair Cell Regeneration.

Mitarbeiter: 68